Melane Sampson, Author at BioTuesdays

Developments

Windtree highlights abstract on istaroxime presented at 2025 THT conference

Windtree Therapeutics (NasdaqCM:WINT) has announced that an abstract discussing the positive results of SEISMiC, its Phase 2b study of istaroximine in cardiogenic shock, was presented by Dr. Matteo Pagnesi, a...

February 12, 2025

Developments

FOX 26 interview with Baylor’s Alastair Thompson discusses achieving clear margins in breast cancer surgery with Perimeter’s investigational B-Series OCT with ImgAssist AI 2.0

A FOX26 news interview featuring Dr. Alastair Thompson, a surgical oncologist at Baylor College of Medicine and the lead principal investigator of Perimeter Medical Imaging AI’s (TSX: PINK; OTC: PYNKF) pivotal trial on...

February 11, 2025

Executive Moves

Titan launches equity research division; names Boris Peaker senior healthcare analyst

Titan Partners Group, a division of American Capital Partners, has announced the launch of its equity research division with the appointment of Boris Peaker, Ph.D., CFA, as managing director and senior equity research...

February 11, 2025

Developments

Firefly accepted into NVIDIA Connect program

Firefly Neuroscience (NASDAQ:AIFF) has announced its acceptance into the NVIDIA Connect program, granting access to advanced software development resources, frameworks, software development kits, and a global ecosystem...

February 11, 2025

Developments

Eledon’s tegoprubart plays key role in recent GM pig kidney transplant

Eledon Pharmaceuticals (NASDAQ:ELDN) has announced that its investigational anti-CD40L antibody, tegoprubart, was used as a key component of the immunosuppression therapy regimen in a patient who recently received a...

February 11, 2025

Developments

Medincell reports completion of Phase 3 trial of olanzapine LAI in schizophrenia

Medincell (EPA:MEDCL) has announced the completion of SOLARIS, its Phase 3 trial of olanzapine LAI in patients with schizophrenia, conducted by Teva Pharmaceuticals (NYSE:TEVA). Medicell reports that it will receive a...

February 10, 2025

Developments

FDA fast tracks Biodexa’s eRapa in FAP

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced that eRapa, a form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), has been granted Fast Track Designation by the FDA...

February 10, 2025

Developments

Firefly congratulates company advisor, Dr. Christopher Wilson, on UW Faculty of Engineering Award for his work on superconducting quantum electronics

Firefly Neuroscience (NASDAQ:AIFF) has announced that Christopher Wilson, Ph.D., has been honored with the prestigious UW Faculty of Engineering Award by the University of Waterloo (UW) for his significant contributions...

February 7, 2025

Developments

Fennec unveils PEDMARQSI in Germany for cisplatin-induced hearing loss in children

Fennec Pharmaceuticals (NASDAQ:FENC; TSX:FRX) announced the commercial launch of PEDMARQSI sodium thiosulfate injection in Germany by Norgine Pharmaceuticals. The treatment is designed to prevent ototoxicity (permanent...

February 7, 2025

Developments

AIM addresses avian flu with follow-up clinical study of Ampligen and FluMist combo

AIM ImmunoTech (NYSE:AIM) has announced plans for a follow-up clinical study to evaluate the potential avian influenza combination therapy of its Ampligen with Astra Zeneca’s (NASDAQ: AZN) FluMist. According to AIM, the...

February 7, 2025

Author - Melane Sampson

Windtree highlights abstract on istaroxime presented at 2025 THT conference

FOX 26 interview with Baylor’s Alastair Thompson discusses achieving clear margins in breast cancer surgery with Perimeter’s investigational B-Series OCT with ImgAssist AI 2.0

Titan launches equity research division; names Boris Peaker senior healthcare analyst

Firefly accepted into NVIDIA Connect program

Eledon’s tegoprubart plays key role in recent GM pig kidney transplant

Medincell reports completion of Phase 3 trial of olanzapine LAI in schizophrenia

FDA fast tracks Biodexa’s eRapa in FAP

Firefly congratulates company advisor, Dr. Christopher Wilson, on UW Faculty of Engineering Award for his work on superconducting quantum electronics

Fennec unveils PEDMARQSI in Germany for cisplatin-induced hearing loss in children

AIM addresses avian flu with follow-up clinical study of Ampligen and FluMist combo

Subscribe